Krishna Institute of Medical Sciences Ltd

Net profit of Krishna Institute of Medical Sciences rose 55.42% to Rs 101.80 crore in the quarter ended March 2025 as against Rs 65.50 crore during the previous quarter ended March 2024. Sales rose 25.73% to Rs 796.90 crore in the quarter ended March 2025 as against Rs 633.80 crore during the previous quarter ended March 2024. For the full year,net profit rose 24.03% to Rs 384.50 crore in the year ended March 2025 as against Rs 310.00 crore during the previous year ended March 2024. Sales rose 21.49% to Rs 3035.10 crore in the year ended March 2025 as against Rs 2498.20 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales796.90633.80 26 3035.102498.20 21 OPM %24.8525.07 -25.7925.49 - PBDT175.80146.30 20 724.50606.00 20 PBT123.20100.00 23 547.30459.50 19 NP101.8065.50 55 384.50310.00 24 Powered by Capital Market - Live

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 12 May 2025.Powered by Capital Market - Live

Krishna Institute of Medical Sciences Ltd fell 7.65% today to trade at Rs 480.7. The BSE Healthcare index is down 0.22% to quote at 38128.73. The index is down 8.88 % over last one month. Among the other constituents of the index, Suven Pharmaceuticals Ltd decreased 4.41% and NGL Fine Chem Ltd lost 4.32% on the day. The BSE Healthcare index went up 9.06 % over last one year compared to the 0.3% fall in benchmark SENSEX. Krishna Institute of Medical Sciences Ltd has lost 21.82% over last one month compared to 8.88% fall in BSE Healthcare index and 5.06% drop in the SENSEX. On the BSE, 6380 shares were traded in the counter so far compared with average daily volumes of 21151 shares in the past one month. The stock hit a record high of Rs 674 on 13 Jan 2025. The stock hit a 52-week low of Rs 350.02 on 04 Jun 2024.Powered by Capital Market - Live

The agreement is for an initial term of 7 years with an extension for a further period of 3 years on an exclusive basis. According to the terms and conditions under of this agreement, KIMS would run, manage, operate, direct and control the hospital and provide the medical services at the hospital. Splendid Hospitals is in the process of constructing a 150-bed hospital, under the name Splendid Hospital, with a total floor area of 1,60,000 square feet. The hospital has the potential due to the location and demand for hospital services and has the capacity to expand to over 200 beds and will be equipped with the latest medical infrastructure, medical and diagnostic equipment, and multiple operation theatres. The hospital is expected to commence operations in June 2025. To ensure the hospital operates efficiently and effectively, Splendid requires the services of a specialized and professional team of experts. Therefore, under the proposed O&M terms, Splendid intends to engage KIMS as the exclusive operator to manage, run, operate, direct, and control the hospital operations, and to provide or facilitate the provision of the medical services as outlined in the relevant schedule of the agreement. In consideration for the medical services fees and in accordance with the terms of this Agreement, KIMS is entitled to receive revenue fee of 9% (nine percent) of the total net revenue. Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana, Andhra Pradesh and Mahrashtra, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. The company's consolidated net profit jumped 23.5% to Rs 88.70 crore in Q3 FY25 as compared with Rs 71.84 crore in Q3 FY24. Net sales increased 27.5% YoY to Rs 772.40 crore in Q3 FY25. Powered by Capital Market - Live

Krishna Institute of Medical Sciences has entered into an Operations and Management Agreement with Splendid Hospitals, Hyderabad, Telangana for an initial term of 7 years with an extension for a further period of 3 years on an exclusive basis, to run, manage, operate, direct and control the Hospital and provide the Medical Services at the Hospital in accordance with the terms and conditions under of this Agreement.Powered by Capital Market - Live

UAIMS Hospital, started in 2022, is one of the most advanced quaternary care hospitals in the Sangli region in Maharashtra. The hospital currently has installed capacity of 356 beds and has potential to expand to 500+ beds. It has latest medical infrastructure including CT, MRI & 15 state-of-the-art operation theatres and a dedicated mother & child care facility spread across an entire floor. It has also announced launch of a comprehensive day care oncology center adjacent to the hospital. This facility is currently under construction and is expected to be operationalised in 2025. The company has taken over the operations and management of UAIMS Hospital, located in Sangli, Maharashtra. This partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years. The new entity will be known as KIMS-UAIMS Hospital. KIMS has already announced 300 bed multi-specialty hospital in Thane slated to commence operations in the first quarter of next financial year. Commenting on its foray into Sangli, Dr Bhaskar Rao, CMD, KIMS Hospitals, said, 'Maharashtra is an important market for us. Our foray into Sangli signifies our commitment to bring our trusted affordable, advanced and accessible healthcare model to more geographies of Maharashtra. We will continue to look for a mix of greenfield and brownfield strategy for ramping up our presence in Maharashtra.' Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana, Andhra Pradesh and Mahrashtra, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost. The company's consolidated net profit jumped 23.5% to Rs 88.70 crore in Q3 FY25 as compared with Rs 71.84 crore in Q3 FY24. Net sales increased 27.5% YoY to Rs 772.40 crore in Q3 FY25. The scrip shed 0.22% to Rs 557.45 on the BSE.Powered by Capital Market - Live

Krishna Institute of Medical Sciences (KIMS) has taken over the operations and management of UAIMS Hospital, located in Sangli, Maharashtra. This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years. The agreements were signed between Dr. Bhaskar Rao, CMD, KIMS Hospitals and Dr. Milind Parikh, Designated Partner of Ushahkal Abhinav Institute of Medical Sciences LLP, owners of UAIMS Hospital. The new entity will be known as KIMS-UAIMS Hospital. In Maharashtra, as a first step, it had acquired a hospital in Nagpur by taking over Kingsway Hospital in 2022. In 2024, it started operations at its second hospital in Nashik. KIMS has already announced 300 bed multi-specialty hospital in Thane slated to commence operations in the first quarter of next financial year. This strategic partnership at Sangli with UAIMS Hospital is in line with KIMS Hospitals strategy to strengthen its presence in the state of Maharashtra. UAIMS Hospital, started in 2022, is one of the most advanced quaternary care hospitals in the Sangli region in Maharashtra. The hospital is spread across over 4 acres of land and has one of the highest floor area to bed ratio. The hospital currently has installed capacity of 356 beds and has potential to expand to 500+ beds. It has latest medical infrastructure including CT, MRI & 15 state-of-the-art operation theatres and a dedicated mother & child care facility spread across an entire floor. UAIMS has focus on critical care and more than 100 critical care beds are available with advanced medical infrastructure. UAIMS has also announced launch of a comprehensive day care oncology center adjacent to the hospital. This facility is currently under construction and is expected to be operationalised in 2025. Powered by Capital Market - Live

Net profit of Krishna Institute of Medical Sciences rose 23.47% to Rs 88.70 crore in the quarter ended December 2024 as against Rs 71.84 crore during the previous quarter ended December 2023. Sales rose 27.49% to Rs 772.40 crore in the quarter ended December 2024 as against Rs 605.84 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales772.40605.84 27 OPM %24.2424.26 - PBDT179.30137.83 30 PBT134.60102.45 31 NP88.7071.84 23 Powered by Capital Market - Live

Krishna Institute of Medical Sci. will hold a meeting of the Board of Directors of the Company on 6 February 2025.Powered by Capital Market - Live

Gross revenue stood at Rs 782 crore during the quarter, registering a growth of 19.4% on YoY basis. Profit before tax grew 11.47% YoY to Rs 99.1 crore in the quarter ended 30 September 2024. Consolidated EBITDA increased by 23.8% YoY to Rs 223 crore and EBITDA margin rose to 28.7% in Q2 FY25 as against 27.6% in Q2 FY24. Krishna Institute's average revenue per occupied bed (ARPOB) rose by 22.9% YoY to Rs 38,263. Average revenue per patient (ARPP) grew by 9.7% YoY to Rs 1,40,316. The company conducted 4.73 lakhs OPD consults in Q2 FY25, which increased by 12.2% on YoY basis. Dr. B Bhaskar Rao, CMD, KIMS Hospitals, said: 'The second quarter has been an extremely busy and productive one on multiple fronts for us. Our unit in Nashik went live this quarter and we are happy to say that we have started our first hospital in Kerala at Kannur. All our units are working to their optimal capacity to meet the rush of patients across all geographies. We have been focusing on ensuring that our mission to provide affordable and accessible quality healthcare reaches everyone effectively. We are confident and on track to achieve our targets for FY 25.' Headquartered in Hyderabad, Krishna Institute of Medical Sciences (KIMS Hospitals) is one of the largest corporate healthcare groups in Telangana and Andhra Pradesh, providing multi-disciplinary integrated healthcare services, with a focus on tertiary and quaternary healthcare at affordable cost.Powered by Capital Market - Live